Researchers developed an antibody-based treatment that targets cadherins on circulating tumor cells, eliminating them in mouse models of breast and pancreatic cancer. The therapy shows promise in preventing cancer metastasis, a leading cause of cancer-related deaths.
A new study combines targeted and immune therapies to overcome limitations in treating cancer. The approach uses antibodies to recognize and target cancer cells, increasing the efficacy of any cancer drug when attached to its disease-related target.
Researchers are studying the interaction between obesity and nitric oxide synthase in triple-negative breast cancer, aiming to develop a new treatment strategy. Another team is investigating the role of NHE6 protein in multiple myeloma resistance to daratumumab treatment, with the goal of improving therapy outcomes for patients.
A recent study supports fourth vaccination for cancer patients to protect them against COVID-19. Patients with solid tumours and hematological cancers showed a significant increase in antibody levels after a fourth dose of one of the currently approved vaccines.
A newly developed agonistic antibody targeting TREM2 reduced amyloid burden and alleviated cognitive decline in mice with Alzheimer's disease. The study suggests that increasing TREM2 activation could have therapeutic effects such as improved cognition.
Researchers developed an AI method to predict how well new COVID-19 variants infect human cells and evade antibodies. The system can analyze a million mutated variants, enabling the development of next-generation antibody therapies and vaccines that provide broader protection against potential future variants.
Researchers at McMaster University have discovered a combination of antiviral drugs and antibody therapies that is more effective than either approach alone. The combination boosts the virus-fighting properties of antibodies, which work by binding to infected cells and triggering the immune system to kill them.
The AABB has released clinical practice guidelines for the appropriate use of COVID-19 convalescent plasma, recommending its use for nonhospitalized patients at high risk for disease progression. The guidelines suggest that CCP is most effective when transfused with high neutralizing titers early after symptom onset.
Researchers developed a broadly neutralizing antibody that neutralized all currently known SARS-CoV-2 variants, including Omicron strains. The antibody works differently from existing antibodies and prevents the virus from fusing with host cells.
A new study by Tokyo University of Science researchers reveals that dendritic cell immunoreceptor (DCIR) plays a crucial role in the development of colorectal tumors. Blocking DCIR may prevent ulcerative colitis and colon cancer, offering a potential therapeutic target for treating these diseases.
A global team of researchers, including Professor Stuart Cook, has won £30M to develop an injectable cure for genetic heart conditions. The team aims to pioneer gene therapy technologies to silence or edit faulty genes causing deadly conditions.
Researchers discovered a potent universal coronavirus therapy that targets the S2 stalk region of the viral spike protein, highly conserved among beta-coronaviruses. The monoclonal antibody protected against infections when given as an intraperitoneal injection or nasal dose in animal experiments.
Researchers analyze delta variant's biophysical characteristics, revealing unique traits that evade neutralizing antibodies and contribute to severe symptoms. The study sheds light on why vaccinated individuals can still contract the virus and why delta variant hospitalizations are higher than other variants.
Researchers from Mayo Clinic Comprehensive Cancer Center found that adding brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma. The study showed that the drug has a positive impact on overall survival, regardless of other treatments administered later in the course of care.
Researchers at the German Primate Center found that emerging Omicron subvariants BA.2.12.1, BA.4, and BA.5 are inhibited less efficiently by existing therapeutic antibodies, which may reduce protection against future infections. The study suggests these variants have acquired biological traits allowing for more efficient transmission.
Scientists at Institut Pasteur developed potent neutralizing antibodies from convalescent COVID-19 individuals effective against various SARS-CoV-2 variants. These human antibodies are promising candidates for immunotherapies to prevent severe forms and/or treat COVID-19 in immunocompromised patients.
Researchers have identified two broadly neutralizing antibodies that can effectively neutralize all SARS-CoV-2 variants, including Omicron BA.1 and BA.2 subtypes. The antibodies, Cv2.1169 and Cv2.3194, were found to be fully active against Alpha, Beta, Gamma, and Delta variants.
Researchers developed an antibody cocktail effective against a Hendra virus variant, neutralizing its ability to mutate and evade recognition. The combination of four antibodies leaves the virus with minimal ability to further evolve, providing significant protection against this global biosecurity threat.
A UVA researcher is using a harmless amoeba to develop an innovative treatment for deadly C. difficile infections in young children. The approach has the potential to deliver specific antibodies directly to the gut, reducing the need for antibiotics and addressing a growing public health threat.
Researchers discovered that pregnant women produce super antibodies to protect their newborns by altering the structure of sugars attached to the antibodies. This molecular change allows immunoglobulin G to stimulate immunity through receptors that respond specifically to deacetylated sugars, providing expanded protective role.
A new combination therapy using a tumor-suppressing lipid molecule and an antibody for cytotoxic T-lymphocyte antigen 4 has been shown to significantly slow tumor growth and enhance the strength of tumor-attacking T cells in liver cancer. This promising approach offers hope for patients with limited treatment options.
Researchers at UC San Diego describe the underlying signaling pathway that causes PAH and a novel monoclonal antibody therapy that blocks abnormal blood vessel formation. The study reveals two opposing roles of NOTCH ligands and opens a door to a potentially new treatment for PAH.
Researchers at Charité, MDC, and FU Berlin have studied the mechanisms of action of antibody and dexamethasone treatments for COVID-19. They found that combination therapy is more effective in reducing viral activity and inflammation in lung tissue, suggesting a potential game-changer in treating severe cases.
The CodeBreaK 100 trial demonstrated prolonged tumor responses and favorable safety profiles in patients treated with sotorasib. Long-term treatment was well-tolerated, with a two-year overall survival rate of 32.5%.
A Johns Hopkins-led study published in New England Journal of Medicine found that convalescent plasma from recovered COVID-19 patients can effectively treat outpatients, with a 54% reduced need for hospitalization. The therapy's effectiveness increases with earlier administration within five days after diagnosis.
Researchers at Yale have identified a remdesivir-resistant variant of the SARS-CoV-2 virus in an immunocompromised patient. The discovery raises concerns about drug resistance in COVID-19 patients, particularly those with weakened immune systems.
Scientists at University of Illinois and Mie University develop monoclonal antibodies to prevent lung cell death in mouse models of idiopathic pulmonary fibrosis and acute respiratory disease syndrome. Non-invasive diagnostic tools also presented could aid in predicting disease progression and identifying patients at risk.
Scientists have discovered a human antibody that effectively neutralizes two types of hantaviruses in animal models, providing a promising candidate for developing a 'pan-hantavirus' therapy. Collectively, hantaviruses cause about 50,000 severe and often fatal infections worldwide each year.
Researchers at La Jolla Institute for Immunology have developed two human antibodies that target Ebola virus and Sudan virus, showing promise for a powerful antiviral therapy. The antibodies, 1C3 and 1C11, can block three glycoprotein sites on the virus at once and target the fusion machinery used by the viruses to infect host cells.
Researchers at Texas Biomedical Research Institute have found that adding an antibody to the widely-used TB vaccine significantly improves its long-term effectiveness. The combination of the vaccine and an IL-10 blocker allows for better control of TB infection in mice, with improved lung health and increased memory immune cells.
Lab tests show antiviral therapies like remdesivir, molnupiravir, and nirmatrelvir remain effective against the BA.2 variant. Some monoclonal antibodies, such as Evusheld, also appear to be more effective against BA.2 than earlier strains.
A study at Duke-NUS Medical School found that inhibiting IL-11 can reduce kidney damage, inflammation, and scarring in Alport syndrome mice. Combining this therapy with ACEi treatment increased lifespan by over 400%.
Researchers discover unique glycoprotein structure of Nipah and Hendra viruses, which could provide blueprint for vaccine design and antibody treatments. The findings suggest a multi-pronged approach to prevent and treat these deadly illnesses.
Research reveals SARS-CoV-2 can have multiple variants in one person, with some hiding in specific cells like kidneys or spleens. This can make complete virus clearance more difficult, as the body struggles to defend against dominant strains.
Researchers at Osaka University identified a new monoclonal antibody target, R8H283, which selectively binds to cancer-specific conformational epitopes on the ubiquitous CD98 heavy chain protein in multiple myeloma cells. This selective binding allows for anti-MM effects without damaging normal host cells.
Researchers analyzed over 1.5 million SARS-CoV-2 genome sequences to understand the evolution of the virus, finding that increased infectivity is a driving force behind its spread. The omicron variant is predicted to compromise current vaccines and therapies, highlighting the need for new generation of vaccines and monoclonal antibodies.
Scientists at Scripps Research identified a common target on the spike protein of multiple coronaviruses, including SARS-CoV-2, that can be targeted by a broad-spectrum vaccine. The discovery could inform the design of effective vaccines and antibody therapies against future coronavirus pandemics.
A groundbreaking study reveals that Ebola virus can hide in the brain ventricular system and cause fatal disease even after treatment. Persistent infection was found in about 20% of monkeys treated with antibody therapeutics, highlighting the need for long-term follow-up of survivors.
A study by MedUni Vienna found that many cancer patients can build up sufficient immunity against SARS-CoV-2 after the third vaccination. However, patients with blood cancers may not develop protection due to immunosuppressive treatments.
Lab tests show current anti-COVID pills remain effective against omicron, but available antibody therapies are substantially less effective. Researchers tested various treatments and found that some antibodies have lost their ability to neutralize omicron at realistic dosages.
A new study finds that the Omicron variant can evade immunity from previous infections and vaccines, with antibodies from double-vaccinated individuals showing reduced neutralizing activity. The study suggests the need for new vaccines and treatments to combat evolving variants.
Researchers found that mRNA vaccines were highly effective (86%) in preventing SARS-CoV-2-related deaths among vaccinated individuals, especially in the elderly population. However, vaccine effectiveness against infection was lower (69%) and decreased with increasing age and comorbidity burden.
Researchers at Mayo Clinic found that mRNA therapy improves the response of patients who weren't responding to cancer immunotherapy. The study identified a weak spot in T cells, white blood cells crucial for fighting cancer, and developed an mRNA-based strategy to enhance their response.
The Liberty Asthma VOYAGE trial found that dupilumab significantly reduced the rate of severe exacerbations by nearly 60% and improved lung function and asthma control in children ages 6 to 11. Dupilumab was also shown to be safe, with minimal adverse reactions.
A team of researchers has discovered a new mechanism by which antibodies can disable viruses. By distorting the virus particles, rather than just blocking their surfaces, antibodies prevent them from infecting host cells. This breakthrough could lead to new treatments for diseases caused by Zika and dengue viruses.
Antibodies that mimic the SARS-CoV-2 virus may explain lingering symptoms of long-haul COVID-19 and rare vaccine side effects like allergic reactions and blood-clotting. This theory, based on classic immunological concepts, suggests a cascade of immune responses that can lead to adverse effects.
Researchers have developed a new strategy to combat the tick-borne Crimean-Congo hemorrhagic fever (CCHF) virus by reconstructing its structure and identifying neutralizing antibodies. The study, published in Science, offers insights for developing therapeutics and vaccines against the virus.
A therapeutic antibody has been shown to unblock and normalise blood vessels inside cancerous tumours, enabling the more effective delivery of targeted cancer treatments. The findings also suggest that inhibiting LRG1 protein production can enhance the effectiveness of immunotherapies, including checkpoint inhibitors and CAR T-cell the...
Itepekimab, a novel monoclonal antibody, has been found to be safe and effective in treating moderate-to-severe asthma. In a phase 2 trial, it significantly improved lung function and reduced asthma control events compared to placebo.
A new study found that infants with high levels of antibody-dependent cellular cytotoxicity (ADCC) against their mother's strain of HIV are less likely to get infected through breastfeeding. The study also showed that ADCC is more effective than neutralizing antibodies in protecting infants against HIV transmission and improving outcomes.
Patients with multiple myeloma often mount a poor antibody response to COVID-19 vaccines and have a weak T cell response, underscoring the need for booster vaccination and safety precautions. Researchers found that these patients are at high risk of severe COVID-19 infection.
Researchers found that Delta and Delta Plus infect lung cells with higher efficiency than the original virus, evading antibodies induced by infection and vaccination. The new variants were also resistant to some therapeutic antibodies, leading to reduced inhibition.
Researchers at Sunnybrook Health Sciences Centre have successfully delivered antibody therapy to breast cancer metastases in the brain using focused ultrasound. The treatment, which temporarily opens the blood-brain barrier, has shown promising results with tumor size reductions of up to 21% in patients.
Researchers evaluated the anti-tumor efficacy of DARA conjugated to DM1 via a non-cleavable linker, demonstrating enhanced therapeutic potency and in vivo stability. The study showed that conjugation did not affect the stability or activity of the biologic, and imaging techniques can be applied to other immunotherapies.
A promising radionuclide treatment has been identified for HER2-positive breast cancer patients, combining radioactive iodine therapy with single-domain antibodies targeting the HER2 antigen. The treatment demonstrates safety and efficacy in a phase I study, paving the way for further clinical development.
A global collaboration has identified three groups of antibodies resistant to mutations in the SARS-CoV-2 Spike protein, which could target vulnerable sites on the protein. The study provides a framework for selecting durable antibody cocktails for COVID-19 treatment and will guide the development of more effective antibody therapies.
TB202-3 binds to a specific area of the SARS-CoV-2 spike protein that has not been impacted by most viral mutations, making it an important candidate for clinical testing. The antibody demonstrates potency against multiple strains of COVID-19, including those with various mutations.
Researchers at MD Anderson Cancer Center presented new findings on novel therapeutic approaches, including cell therapy for solid tumors and antibody drug conjugates targeting TROP2. The therapies achieved partial responses in six patients, with an overall response rate of 35.3% and disease control rate of 70.6%.
Researchers have created a new technology to enhance therapeutic antibodies' ability to attack blood cancer cells by leveraging the human immune system. This approach combines IgM and IgG antibodies, resulting in a single molecule with increased complement activation.
Researchers at WashU Medicine have identified an antibody that is highly protective at low doses against a wide range of viral variants. The antibody targets a part of the virus' spike protein that differs little across variants, making it unlikely to lose potency as the virus mutates.